Abstract
In the absence of sufficient testing capacity for COVID-19, a substantial number of infecteds are expected to remain undetected. Since the undetected cases are not quarantined, they are expected to transmit the infection at a much higher rate than their quarantined counterparts. That is, under the lack of extensive random testing, the actual prevalence and incidence of the SARS-CoV-2 infection may be entirely different from that being reported. Thus, it is imperative that the information on the percentage of undetected (or unreported) cases be considered while estimating the parameters and forecasting the transmission dynamics of the epidemic.
In this paper, we have developed a new version of the basic susceptible-infected-removed (SIR) compartmental model, called the susceptible-infected (quarantined/ free) -recovered-deceased [SI(Q/F)RD] model, to incorporate the impact of undetected cases on the transmission dynamics of the epidemic. Further, we have presented a Dirichlet-Beta state-space formulation of the SI(Q/F)RD model for the estimation of its parameters using posterior realizations from Gibbs sampling procedure. As a demonstration, the proposed methodology is implemented to forecast the COVID-19 transmission in California and Florida.
Highlights
Data calibrated for underreporting using excess deaths and case fatality rate.
A new extension of SIR compartmental model, called SI(Q/F)RD, is introduced.
A Dirichlet-Beta state-space formulation of the SI(Q/F)RD model is developed.
Gibbs sampling used to estimate the Bayesian hierarchical state-space model.
Proposed methodology is applied on the COVID-19 data of California and Florida.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos